日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Key vaccine in high demand, but supplies short

By LIU ZHIHUA | China Daily | Updated: 2019-07-05 07:08
Share
Share - WeChat
A woman has a 9-valent vaccine shot in Zhengzhou, capital of Henan province. Each year, some 131,500 new cervical cancer cases are reported in China, and about 53,000 patients die from the disease. ZHANG TAO/FOR CHINA DAILY

Once people can acquire the vaccination on a regular basis, the balance between supply and demand will be gradually restored, he said.

According to a report released earlier this year by Horizon Insights, a consultancy in Shanghai, some 300 million Chinese are in the recommended age group for the 2-valent vaccine, 130 million for the 4-valent, and 90 million for the 9-valent. Every year, 8 million people fall into the recommended age group for each vaccine.

Last year, 300,000 people were vaccinated with the 2-valent type, 1.1 million with the 4-valent, and only 100,000 with the 9-valent, resulting in market values of 500 million yuan, 2.7 billion yuan and 400 million yuan, the report said.

About 833,300 doses of the 2-valent vaccine, 3.41 million of the 4-valent and 1.22 million of the 9-valent were released on the market last year, according to the report.

It estimated that the market value for the 2-, 4-and 9-valent vaccines would reach 1 billion yuan, 7.2 billion yuan and 10 billion in times of peak demand.

There will continue to be a shortage of all three types until next year, as the huge demand that exists now cannot be met in a short period, the report said.

Zhao Heng, founder of consulting company Latitude Health, said the shortage could be resolved through increased production and distribution, but as the three types of vaccine are not on the national compulsory vaccination program, it is difficult for the authorities to order pharmaceutical companies to increase supplies.

However, more than a dozen Chinese pharmaceutical companies are developing HPV vaccines ranging from 2-valent to 14-valent, and some have started phase-3 clinical trials while others have only just received approval for such trials, according to the Horizon Insights report.

|<< Previous 1 2 3 4   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 亚洲第一区视频在线观看 | 国产免费一区二区三区免费视频 | 久久精品中文字幕 | 精品国产一区二区三区久久久 | 婷婷综合色 | 久久久精| 黄色视屏免费观看 | 青草国产视频 | 精品美女在线观看视频在线观看 | 欧美综合在线观看 | 欧美成a人片在线观看久 | 殴美一区 | 欧美久久久久久 | 欧美精品一区二区在线观看 | 成人嘿嘿视频网站在线 | 无码国产精品成人午夜视频 | 日本精品久久久久中文字幕 | 黄色一级大片在线免费看产 | 亚洲日本va中文字幕线 | 最新日本中文字幕在线观看 | 久久精品欧美一区二区三区不卡 | 日韩一区免费在线观看 | 亚洲精品在线观看视频 | 欧美日韩视频在线第一区 | 波多野结衣在线免费播放 | 亚洲国产午夜 | 天天干天天色 | 免费国产成人高清视频网站 | 大片毛片| 欧美高潮| 国产精品久久久久一区二区 | 狠狠色噜噜狠狠狠狠色吗综合 | 97视频久久久 | 免费看在线偷拍视频 | 亚洲一区二区免费视频 | 国产精品果冻麻豆精东天美 | 国产精品免费视频网站 | 男女做性无遮挡免费视频 | 福利视频中文在线观看 | 老头巨大校花体内驰骋小说文 | 亚洲精品日韩精品一区 |